Pre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne Phase 3 clinical trial of denifanstat in moderate to ...

Please provide your email address to receive an email when new articles are posted on . The photopneumatic device improved acne in 66.7% of patients in this 7-week trial. Improvements were seen across ...

An acne management guideline was updated, which includes new considerations for isotretinoin, hormonal therapies, new topical ...

A look at the most common medications used in patients with acne. Casey Butrus, PharmD: Hilary, we have many different treatment options for acne, different mechanisms of action that have been around ...

Secured equity financing with gross proceeds of $175M in April 2026Phase 3 clinical trial of denifanstat in moderate to severe acne patients for ...

The treatment of acne ( Table I) [1,2,3,4,5,6] is based upon its severity (mild, moderate, severe) and the type(s) of lesion(s) present (noninflammatory, inflammatory, mixed). In general, the ...

Please provide your email address to receive an email when new articles are posted on . IDP-126 — a combination of clindamycin, adapalene and benzoyl peroxide — reduced acne severity in about half of ...

Denifanstat met all endpoints in a Phase 3 acne trial and showed favorable tolerability. Sagimet also launched a Phase 1 trial for TVB-3567. Sagimet Biosciences announced that its oral fatty acid ...

BRISBANE, Calif.--(BUSINESS WIRE)--Ninety percent of moderate to severe acne sufferers said having acne-free skin would dramatically change the way they live their life, according to a new survey ...

Among nearly 20 different agents and treatment combinations, topical triple-agent fixed-dose combination (FDC) gel emerged as the most efficacious for moderate-to-severe acne. Researchers who ...

It’s the bane of many people’s existences – acne. It can feel like the only thing you see when you look at a photo or when you’re putting on makeup. Acne can cause not only skin discomfort and ...